Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $28.5 million.

  • Coherus Oncology's Net Income towards Common Stockholders fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • According to the latest figures from FY2024, Coherus Oncology's Net Income towards Common Stockholders is $28.5 million, which was up 111.98% from -$237.9 million recorded in FY2023.
  • Coherus Oncology's 5-year Net Income towards Common Stockholders high stood at $132.2 million for FY2020, and its period low was -$291.8 million during FY2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$237.9 million (2023), whereas its average is -$167.0 million.
  • Per our database at Business Quant, Coherus Oncology's Net Income towards Common Stockholders tumbled by 317.16% in 2021 and then spiked by 111.98% in 2024.
  • Coherus Oncology's Net Income towards Common Stockholders (Yearly) stood at $132.2 million in 2020, then plummeted by 317.16% to -$287.1 million in 2021, then declined by 1.62% to -$291.8 million in 2022, then increased by 18.46% to -$237.9 million in 2023, then spiked by 111.98% to $28.5 million in 2024.